


Supplemental Figures for:

Female representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies

Jonathan M Loree et al.

Supplementary Figure 1: Odds Ratio for female trial enrollment versus very high human development index country incidence or mortality



Caption: 1A) Odds Ratio (OR) for female trial enrollment compared to incidence by tumor type within very high human development index (HDI) countries and **1B)** OR for female trial enrollment compared to mortality in very high HDI countries.

Subcaption: Sex-specific cancers have been excluded. Female to male ratio (female:male) for trial enrollment and population incidence, OR and *P* value shown on the right.

Supplementary Figure 2: Odds Ratio for female trial enrollment versus global incidence or mortality

Α

Trial Global Enrollment Female:Male Incidence Female:Male Odds P Value Ratio Thyroid 0.82 3.33 0.25 < 0.0001 Melanoma < 0.0001 0.72 0.91 0.80 Bladder 0.41 < 0.0001 0.30 1.38 Kidnev 0.38 0.58 0.64 0.0001 Pancreas 0.77 0.89 0.87 0.0025 Colorectal 0.66 0.80 0.83 < 0.0001 Lung 0.67 0.53 1.27 < 0.0001 Multiple Myeloma 0.76 0.78 0.98 0.37 Lymphoma 0.78 0.78 1.00 0.88 Leukemia 0.68 0.75 0.90 < 0.0001 All Cancers < 0.0001 0.67 0.65 1.04 2.0 0.0 0.5 1.0 1.5 Women less likely to Women more likely to be enrolled in trials be enrolled in trials В Trial Global Enrollment Female:Male Mortality Odds Female:Male Ratio P Value Thyroid 0.82 1.64 0.50 < 0.0001 Melanoma 0.72 0.74 0.98 0.26 Bladder 0.41 0.35 1.17 0.0022 Kidney < 0.0001 0.38 0.54 0.70 Pancreas 0.77 0.90 0.86 0.0006 Colorectal 0.66 0.82 0.81 < 0.0001 Lung 0.67 0.49 1.39 < 0.0001 **Multiple Myeloma** 0.76 0.80 0.95 0.049 Lymphoma 0.78 0.70 1.11 < 0.0001 Leukemia 0.68 0.72 0.94 0.0070 All Cancers 0.67 0.59 1.15 < 0.0001 1.5 0.5 1.0 2.0 0.0

> Women less likely to be enrolled in trials


Caption: 2A) Odds Ratio (OR) for female trial enrollment compared to incidence globally by tumor type. *2B)* OR for female trial enrollment compared to mortality globally.

Women more likely to

be enrolled in trials

Subcaption: Sex-specific cancers have been excluded. Female to male ratio (female:male) for trial enrollment and population incidence, OR and *P* value shown on the right.

Supplementary Figure 3: Female and male distribution across US incidence, US mortality and 153 trials for 10 tumor types



Caption: Graphical representation of the ratio of females to males (female:male) within each of the 149 trials leading to FDA drug approvals during the period reviewed for the 10 most common non sex-specific tumor types in the US. The center of each circle specifies the tumor type represented. The inner ring denotes the female: male US incidence for that tumor type and the middle ring denotes the female:male US mortality for that tumor type. The outer ring of each circle represents female:male enrollment within each trial for that tumor.